Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received lenvatinib were included. Univariate analysis showed tha...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Portfolio 2021-07-01
Serier:	Scientific Reports
Online adgang:	https://doi.org/10.1038/s41598-021-93794-5
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!